📢 [Key Milestone] BioMAdvanced Diagnostics enters an agreement with Nantes’ University Hospital to analyze anonymized clinical data from 300 kidney... View Article
Author Archives for Adeline Chauvigné
BioMAdvanced Diagnostics: agreement with Nantes University Hospital to use anonymized clinical data from 300 kidney transplant patients
1 November 2025📢 [Key Milestone] BioMAdvanced Diagnostics enters an agreement with Nantes’ University Hospital to analyze anonymized clinical data from 300 kidney... View Article
Naobios delivers Flugen Inc’s M2SR influenza vaccine candidate for upcoming clinical trials
Naobios’ development work and GMP manufacturing of vaccine clinical batches enables FluGen to conduct its 2022 clinical trials in the... View Article
Naobios delivers Flugen Inc’s M2SR influenza vaccine candidate for upcoming clinical trials
1 November 2025Naobios’ development work and GMP manufacturing of vaccine clinical batches enables FluGen to conduct its 2022 clinical trials in the... View Article
Apellis expands R&D collaboration with Affilogic to develop targeted complement therapies for delivery into the brain
Apellis Pharmaceuticals and Affilogic announced that the companies have expanded their research and development (R&D) collaboration, which was initially formed... View Article
Apellis expands R&D collaboration with Affilogic to develop targeted complement therapies for delivery into the brain
1 November 2025Apellis Pharmaceuticals and Affilogic announced that the companies have expanded their research and development (R&D) collaboration, which was initially formed... View Article
VLA2001 becomes the first COVID-19 vaccine to receive a standard marketing authorization in Europe
Valneva receives marketing authorization in Europe for inactivated whole-virus COVID-19 vaccine VLA2001 Valneva , a specialty vaccine company, today announced... View Article
VLA2001 becomes the first COVID-19 vaccine to receive a standard marketing authorization in Europe
1 November 2025Valneva receives marketing authorization in Europe for inactivated whole-virus COVID-19 vaccine VLA2001 Valneva , a specialty vaccine company, today announced... View Article
Valneva receives marketing authorization in Europe for inactivated whole-virus COVID-19 vaccine VLA2001
VLA2001 becomes the first COVID-19 vaccine to receive a standard marketing authorization in Europe Valneva, a specialty vaccine company, today... View Article
Valneva receives marketing authorization in Europe for inactivated whole-virus COVID-19 vaccine VLA2001
1 November 2025VLA2001 becomes the first COVID-19 vaccine to receive a standard marketing authorization in Europe Valneva, a specialty vaccine company, today... View Article
Valneva announces settlement agreement with the UK Government
Valneva, a specialty vaccine company, today announced that it has entered into a settlement agreement with the Government of the... View Article
Valneva announces settlement agreement with the UK Government
1 November 2025Valneva, a specialty vaccine company, today announced that it has entered into a settlement agreement with the Government of the... View Article
OSE Immunotherapeutics announces collaboration with Microsoft
OSE selected by Microsoft France to join the “Biotech Scaler Program” launched during “Viva Technology”, the European Startup and Tech... View Article
OSE Immunotherapeutics announces collaboration with Microsoft
1 November 2025OSE selected by Microsoft France to join the “Biotech Scaler Program” launched during “Viva Technology”, the European Startup and Tech... View Article
Safety and efficacy results of LIS1, a new induction treatment in organ transplantation by the French biotech XENOTHERA
Results from the clinical trial of LIS1, XENOTHERA’s polyclonal glyco-humanised antibody and induction immunosuppressant in solid organ transplantation, were presented... View Article
Safety and efficacy results of LIS1, a new induction treatment in organ transplantation by the French biotech XENOTHERA
1 November 2025Results from the clinical trial of LIS1, XENOTHERA’s polyclonal glyco-humanised antibody and induction immunosuppressant in solid organ transplantation, were presented... View Article
Owkin announces multi-year clinical data science strategic collaboration with Bristol Myers Squibb
Owkin announced that it has entered into a multi-year, strategic collaboration with Bristol Myers Squibb to apply Owkin’s Artificial Intelligence... View Article
Owkin announces multi-year clinical data science strategic collaboration with Bristol Myers Squibb
1 November 2025Owkin announced that it has entered into a multi-year, strategic collaboration with Bristol Myers Squibb to apply Owkin’s Artificial Intelligence... View Article
EMA accepts filing of marketing authorization application for Valneva’s inactivated COVID-19 vaccine candidate
Valneva, a specialty vaccine company, confirmed that the European Medicines Agency (“EMA”) has accepted the filing of a marketing authorization... View Article
EMA accepts filing of marketing authorization application for Valneva’s inactivated COVID-19 vaccine candidate
1 November 2025Valneva, a specialty vaccine company, confirmed that the European Medicines Agency (“EMA”) has accepted the filing of a marketing authorization... View Article